<scp>HCV</scp>‐associated <scp>B</scp>‐cell non‐<scp>H</scp>odgkin lymphomas and new direct antiviral agents

Carrier, Paul; Jaccard, Arnaud; Jacques, J.; Tabouret, Tessa; Debette-Gratien, Marilyne; Abraham, Julie; Mesturoux, Laura; Marquet, Pierre; Alain, Sophie; Sautereau, Denis; Essig, Marie; Loustaud‐Ratti, Véronique

doi:10.1111/liv.12897

Cited by 64 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, 3 published cases have reported successful antiviral treatment in HCV-associated DLBCL using sofosbuvir-based regimens. Carrier et al [5] reported 2 patients who developed SVR with a sofosbuvir-daclatsvir antiviral regimen, but treatment of HCV-infection was initiated only after clinical remission of the lymphoma was declared. Likewise, Romagnoli et al [6] achieved SVR in an HCV-infected patient in remission from DLBCL using sofosbuvir, ribavirin, and IFN.…”

Section: Discussionmentioning

confidence: 99%

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Ewers¹,

Shah²,

Carmichael³

et al. 2016

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is associated with the development of non-Hodgkin lymphomas. For aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL), treatment of HCV infection is typically deferred in treatment-naive patients until after completion of lymphoma therapy [1, 2]. We report a case of HCV-associated stage IV DLBCL successfully treated concurrently using chemoimmunotherapy and a sofosbuvir-based antiviral regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Ewers¹,

Shah²,

Carmichael³

et al. 2016

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…There are very few data to assess how DAAs will affect clinical outcome in patients with extrahepatic manifestations of chronic hepatitis C 57. While it is clear that the presence of mixed cryoglobulinaemia was a predictive factor of poor response to IFN-based therapy,58 to what extent the use of DAAs may change treatment outcomes in this group of patients deserves further study.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1

Zoulim

Liang

Gerbes

et al. 2015

Gut

135

132

View full text Add to dashboard Cite

Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in ‘hard-to-treat’ groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.

show abstract

“…Five patients were already reported in the literature [10][11][12] and were included with updated follow-up. Approval for this study, which was based on the use of archival or cohort data, was obtained from the Institutional Review Boards of the participating centers.…”

Section: Study Design and Patientsmentioning

confidence: 99%

“…However, data on the efficacy of IFN-free regimens 10 in HCVassociated lymphoproliferative disorders are scanty and based on clinical reports. 11,12 In this study, we have evaluated the virological and lymphoproliferative disease response (LDR) rates and toxicity of DAAs in a large series of patients with indolent lymphoproliferative disorders treated by DAAs in the absence of immunochemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Arcaini

Besson

Frigeni

et al. 2016

Blood

Self Cite

160

131

View full text Add to dashboard Cite

Key Points• Direct-acting antiviral agents are able to induce lymphoma response in patients with HCV-associated indolent nonHodgkin lymphoma.• The highest rate of lymphoma response (73%) was observed in patients with marginal zone lymphoma.Regression of hepatitis C virus (HCV)-associated lymphoma with interferon (IFN)-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCVrelated lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs. The histological distribution was 37 marginal zone lymphomas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified. Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other DAAs. The median duration of DAA therapy was 12 weeks (range, 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); the overall LDR rate was 67%, including 12 patients (26%) who achieved a complete response. The LDR rate was 73% among patients with MZL, whereas no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 who were initially positive. After a median follow-up of 8 months, 1-year progression-free and overall survival rates were 75% (95% confidence interval [CI], 51-88] and 98% [95% CI, 86-100], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting.

show abstract

HCV‐associated B‐cell non‐Hodgkin lymphomas and new direct antiviral agents

Cited by 64 publications

References 18 publications

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Contact Info

Product

Resources

About